EP3820866A4 - Pyridine carboxamide compounds for inhibiting nav1.8 - Google Patents
Pyridine carboxamide compounds for inhibiting nav1.8 Download PDFInfo
- Publication number
- EP3820866A4 EP3820866A4 EP19833816.2A EP19833816A EP3820866A4 EP 3820866 A4 EP3820866 A4 EP 3820866A4 EP 19833816 A EP19833816 A EP 19833816A EP 3820866 A4 EP3820866 A4 EP 3820866A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- inhibiting
- pyridine carboxamide
- carboxamide compounds
- compounds
- pyridine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002401 inhibitory effect Effects 0.000 title 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical class NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
- C07D213/85—Nitriles in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862695571P | 2018-07-09 | 2018-07-09 | |
PCT/US2019/041029 WO2020014246A1 (en) | 2018-07-09 | 2019-07-09 | Pyridine carboxamide compounds for inhibiting nav1.8 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3820866A1 EP3820866A1 (en) | 2021-05-19 |
EP3820866A4 true EP3820866A4 (en) | 2022-04-06 |
Family
ID=69141639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19833816.2A Pending EP3820866A4 (en) | 2018-07-09 | 2019-07-09 | Pyridine carboxamide compounds for inhibiting nav1.8 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20220227732A1 (en) |
EP (1) | EP3820866A4 (en) |
JP (1) | JP2021530478A (en) |
KR (1) | KR20210019581A (en) |
CN (1) | CN112689633A (en) |
AU (1) | AU2019301628A1 (en) |
CA (1) | CA3105657A1 (en) |
SG (1) | SG11202100130QA (en) |
WO (1) | WO2020014246A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020176763A1 (en) | 2019-02-27 | 2020-09-03 | Vertex Pharmaceuticals Incorporated | Dosage form comprising prodrug of na 1.8 sodium channel inhibitor |
WO2020219867A1 (en) | 2019-04-25 | 2020-10-29 | Vertex Pharmaceuticals Incorporated | Pyridone amide co-crystal compositions for the treatment of pain |
CN112390745B (en) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | Pyridine nicotinamide derivatives, preparation method and medical application thereof |
PE20221515A1 (en) * | 2019-09-12 | 2022-10-04 | Shanghai Jemincare Pharmaceuticals Co Ltd | PYRIDINE OXINITRIDE, METHOD FOR ITS PREPARATION AND USE OF THIS |
CR20220316A (en) | 2019-12-06 | 2022-10-07 | Vertex Pharma | Substituted tetrahydrofurans as modulators of sodium channels |
WO2022188872A1 (en) * | 2021-03-11 | 2022-09-15 | 上海济煜医药科技有限公司 | Crystal form of pyridine nitrogen oxide compound and use thereof |
IL305721A (en) * | 2021-03-11 | 2023-11-01 | Latigo Biotherapeutics Inc | Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use |
CN117794918A (en) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | Substituted tetrahydrofuran analogues as sodium channel modulators |
WO2022256702A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
AR126073A1 (en) | 2021-06-04 | 2023-09-06 | Vertex Pharma | N-(HYDROXYALKYL(HETERO)ARYL)TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS |
EP4347584A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
JP2024520649A (en) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Solid dosage forms and administration regimens comprising (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl)tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide |
EP4347033A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
WO2023160509A1 (en) * | 2022-02-25 | 2023-08-31 | 中国科学院上海药物研究所 | Amidine derivative compound, and preparation method therefor and use thereof |
WO2023186102A1 (en) * | 2022-04-02 | 2023-10-05 | 武汉人福创新药物研发中心有限公司 | Nav1.8 inhibitor and use thereof |
US20230373925A1 (en) | 2022-04-22 | 2023-11-23 | Vertex Pharma | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023211990A1 (en) | 2022-04-25 | 2023-11-02 | Siteone Therapeutics, Inc. | Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain |
TW202400560A (en) * | 2022-04-28 | 2024-01-01 | 南韓商愛思開生物製藥股份有限公司 | N-oxide compounds and use thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004238361A (en) * | 2003-02-07 | 2004-08-26 | Tosoh Corp | Pyrimidine-5-carboxamide derivative, its intermediate and method for producing the same |
US20090099233A1 (en) * | 2007-10-11 | 2009-04-16 | Pramod Joshi | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
WO2009049181A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
WO2010049302A1 (en) * | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
WO2014120815A1 (en) * | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
WO2015010065A1 (en) * | 2013-07-19 | 2015-01-22 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
WO2019014352A1 (en) * | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL64220A (en) * | 1980-11-21 | 1985-06-30 | May & Baker Ltd | Nicotinamide derivatives,their preparation and their use as herbicides |
DE19946852A1 (en) * | 1999-09-30 | 2001-04-05 | Bayer Ag | Substituted N-phenylphenoxynicotinic acid (thio) amides |
NZ534197A (en) * | 2002-02-11 | 2007-01-26 | Pfizer | Nicotinamide derivatives useful as PDE4 inhibitors |
CN1863785A (en) * | 2003-08-08 | 2006-11-15 | 沃泰克斯药物股份有限公司 | Compositions useful as inhibitors of voltage-gated sodium channels |
ES2285517T3 (en) * | 2003-10-31 | 2007-11-16 | Warner-Lambert Company Llc | PYRIMIDINS AS PHOSFOINOSITIDA-3-KINASES INHIBITORS (PI3K). |
NZ584519A (en) * | 2007-10-11 | 2012-07-27 | Vertex Pharma | Aryl amides useful as inhibitors of voltage-gated sodium channels |
CN102850321A (en) * | 2011-06-28 | 2013-01-02 | 中国科学院上海药物研究所 | Aroxylpyrimidine formamide or aroxylpyridine formamide compound and its preparation method, pharmaceutical composition, and application |
-
2019
- 2019-07-09 CA CA3105657A patent/CA3105657A1/en active Pending
- 2019-07-09 SG SG11202100130QA patent/SG11202100130QA/en unknown
- 2019-07-09 CN CN201980058952.XA patent/CN112689633A/en active Pending
- 2019-07-09 WO PCT/US2019/041029 patent/WO2020014246A1/en active Search and Examination
- 2019-07-09 US US17/256,781 patent/US20220227732A1/en active Pending
- 2019-07-09 EP EP19833816.2A patent/EP3820866A4/en active Pending
- 2019-07-09 KR KR1020217004054A patent/KR20210019581A/en active Search and Examination
- 2019-07-09 JP JP2021500411A patent/JP2021530478A/en active Pending
- 2019-07-09 AU AU2019301628A patent/AU2019301628A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004238361A (en) * | 2003-02-07 | 2004-08-26 | Tosoh Corp | Pyrimidine-5-carboxamide derivative, its intermediate and method for producing the same |
US20090099233A1 (en) * | 2007-10-11 | 2009-04-16 | Pramod Joshi | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
WO2009049180A2 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
WO2009049181A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
WO2010049302A1 (en) * | 2008-10-29 | 2010-05-06 | F. Hoffmann-La Roche Ag | Novel phenyl amide or pyridil amide derivatives and their use as gpbar1 agonists |
WO2014120815A1 (en) * | 2013-01-31 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Quinoline and quinazoline amides as modulators of sodium channels |
WO2015010065A1 (en) * | 2013-07-19 | 2015-01-22 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
WO2019014352A1 (en) * | 2017-07-11 | 2019-01-17 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 32, 30 July 2013 (2013-07-30), pages 12122 - 12134, XP055675708, ISSN: 0002-7863, DOI: 10.1021/ja406223k * |
Also Published As
Publication number | Publication date |
---|---|
JP2021530478A (en) | 2021-11-11 |
EP3820866A1 (en) | 2021-05-19 |
AU2019301628A1 (en) | 2021-01-28 |
CA3105657A1 (en) | 2020-01-16 |
KR20210019581A (en) | 2021-02-22 |
US20220227732A1 (en) | 2022-07-21 |
WO2020014246A1 (en) | 2020-01-16 |
SG11202100130QA (en) | 2021-02-25 |
CN112689633A (en) | 2021-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3820866A4 (en) | Pyridine carboxamide compounds for inhibiting nav1.8 | |
EP3873468A4 (en) | 2-amino-n-phenyl-nicotinamides as nav1.8 inhibitors | |
IL282468A (en) | 2- amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors | |
IL288236A (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
EP3820860A4 (en) | Pyridazine compounds for inhibiting nav1.8 | |
EP3583507A4 (en) | Blockchain-based admission processes for protected entities | |
EP3836923A4 (en) | Pyrrolo - dipyridine compounds | |
EP3725779A4 (en) | Substituted pyridazinone compound | |
EP3765522A4 (en) | Anti-claudin 18.2 antibodies | |
EP3601250A4 (en) | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds | |
EP3915082A4 (en) | Oilfield system | |
IL267139A (en) | Method for producing 5-(1-phenyl-1h-pyrazole-4-yl)-nicotinamide derivatives and similar compounds without isolating or purifying the phenylhydrazine intermediate | |
EP3769610A4 (en) | Planting method for morels | |
EP3870179A4 (en) | Usp7 inhibition | |
EP3687537A4 (en) | Novel usp7 inhibitors for treating multiple myeloma | |
EP3828174A4 (en) | Pyridazinone derivative | |
EP3946288A4 (en) | Substituted 5-cyclopropyl-1h-pyrazol-3-yl-amine derivatives as selective cdk12/13 inhibitors | |
EP3873439A4 (en) | Spak kinase inhibitors as neuroprotective agents | |
EP3712139A4 (en) | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds | |
EP3193610A4 (en) | Selective nav1.7 inhibitors for the treatment of diabetes | |
KR20180002275U (en) | plow for trackter | |
EP3774768A4 (en) | Substituted pyrazole derivatives as selective cdk12/13 inhibitors | |
EP3755267A4 (en) | Extracts for the regeneration of ligaments | |
EP3710001A4 (en) | Compounds and methods for regulating, limiting, or inhibiting avil expression | |
EP3608314A4 (en) | 2,6-disubstituted pyridine derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20210209 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40048215 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20220307 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 29/00 20060101ALI20220301BHEP Ipc: C07D 413/12 20060101ALI20220301BHEP Ipc: C07D 401/12 20060101ALI20220301BHEP Ipc: C07D 213/56 20060101ALI20220301BHEP Ipc: C07D 417/12 20060101AFI20220301BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20231010 |